SKAN Group AG/Fr. SKAN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About SKAN Group AG
SKAN Group AG is engaged in the design and manufacture of advanced cleanroom equipment and solutions, primarily servicing the pharmaceutical and biotechnology industries. It specializes in the development of isolator technology used for aseptic production processes, providing critical equipment that ensures sterile manufacturing environments. Founded in 1968, SKAN is headquartered in Allschwil, Switzerland, and has established a strong presence across the global market, including locations in North America, Europe, and Asia. The company's strategic focus lies in its expertise in containment solutions and decontamination processes, which positions it as a key player in supporting its clients’ compliance with stringent safety and quality regulations. SKAN's innovative approach and specialized knowledge have made its products integral to various high-tech pharmaceutical production lines.
- Ticker
- Fr. SKAN
- Sector
- Health
- Primary listing
- XSWX
- Employees
- 1,694
- Headquarters
- Allschwil, Switzerland
- Website
- skan.com
SKAN Group AG Metrics
BasicAdvanced
CHF 1.7B
56.54
CHF 1.33
0.73
CHF 0.22
0.15%
Price and volume
Market cap
CHF 1.7B
Beta
0.73
52-week high
CHF 77.40
52-week low
CHF 35.75
Average daily volume
43K
Dividend rate
CHF 0.22
Financial strength
Current ratio
1.269
Quick ratio
0.621
Long term debt to equity
1.032
Total debt to equity
1.041
Dividend payout ratio (TTM)
16.50%
Interest coverage (TTM)
20.16%
Profitability
EBITDA (TTM)
49.828
Gross margin (TTM)
74.92%
Net profit margin (TTM)
8.25%
Operating margin (TTM)
10.74%
Effective tax rate (TTM)
11.72%
Revenue per employee (TTM)
CHF 210,000
Management effectiveness
Return on assets (TTM)
5.66%
Return on equity (TTM)
20.25%
Valuation
Price to earnings (TTM)
56.538
Price to revenue (TTM)
4.667
Price to book
14.83
Price to tangible book (TTM)
16.76
Price to free cash flow (TTM)
85.015
Free cash flow yield (TTM)
1.18%
Free cash flow per share (TTM)
0.887
Dividend yield (TTM)
0.29%
Forward dividend yield
0.15%
Growth
Revenue change (TTM)
9.37%
Earnings per share change (TTM)
85.36%
3-year revenue growth (CAGR)
7.09%
10-year revenue growth (CAGR)
32.76%
3-year earnings per share growth (CAGR)
3.13%
10-year earnings per share growth (CAGR)
-0.22%
3-year dividend per share growth (CAGR)
-4.17%
10-year dividend per share growth (CAGR)
0.96%
What the Analysts think about SKAN Group AG
Analyst ratings (Buy, Hold, Sell) for SKAN Group AG stock.
Analyst projections of the future price of SKAN Group AG stock.
Bulls say / Bears say
H1 order intake rose 16.3% to CHF 247.6 million and the backlog grew 27.8% to CHF 442.3 million, giving SKAN a larger base of work to convert into future sales. (EQS News)
Services & Consumables sales climbed 47.2% and reached 39.3% of group sales, while the segment kept a 20.1% EBITDA margin. A larger, higher-margin service business could make earnings less dependent on equipment projects. (EQS News)
SKAN’s aseptic manufacturing systems are positioned to benefit from capacity investment in biosimilars and newer therapies, while H1 saw particularly strong demand for high-speed lines using its E-beam technology. (EQS News)
Customers are making investment decisions more selectively, decision cycles are longer and competition has intensified; management also disclosed CHF 15–20 million of backlog that remains exposed to cancellation. That could delay or reduce the conversion of orders into sales. (EQS News, Stock Analysis)
The H1 EBITDA margin was 9.3%, below the full-year target of 13–15%, and Equipment & Solutions delivered only a 2.3% margin. SKAN therefore needs a strong second half of execution and profitability improvement to meet guidance. (EQS News)
At CHF 72, the shares implied roughly 50 times 2026 earnings estimates in an October analysis. That demanding multiple leaves the stock vulnerable if growth or the expected margin recovery disappoints. (schweizeraktien.net)
Data summarised monthly by Lightyear AI. Last updated on 31 Oct 2026.
SKAN Group AG Financial Performance
Revenues and expenses
SKAN Group AG Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing SKAN Group AG
AllUSDEURGBP
Fund name | Fund size | Fr. SKAN weighting |
|---|---|---|
Xtrackers MSCI Europe Small Cap£XXSC | $3.6B | 0.07% |
Xtrackers MSCI Europe Small Cap€DX2J | $3.6B | 0.07% |
Xtrackers MSCI World Small Cap$XSWC | $183M | 0.01% |
Vanguard ESG Developed Europe All Cap£V3EA | €125M | 0.01% |
Vanguard ESG Developed Europe All Cap£V3EL | €35M | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.